Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Sarah Ellam
Institution:
Evotec (United Kingdom)
Observed institution:
Evotec (United Kingdom)
OpenAlex ID:
A5114566348
Optimisation of a novel series of ENaC inhibitors, leading to the selection of the long-acting inhaled clinical candidate ETD001, a potential new treatment for cystic fibrosis
2024
·
Henry Danahay
, Martin Gosling
, et al.
·
European Journal of Medicinal Chemistry
·
6
Show more works
View as search
Works count:
1
Citation count:
6
H-index:
1
I10-index:
Year
Topic
Type
